Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
Market Watch, The Wall Street Journal, 17 Jul 2012
Accessed on 23 Jul 2012 from http://www.marketwatch.com/story/active-biotech-announce-that-european-medicines-agency-accepts-start-of-scientific-review-of-the-marketing-authorization-application-for-laquinimod-in-relapsing-remitting-multiple-sclerosis-2012-07-17.